[156 Pages Report] Mycoplasma is a common source of contamination in biopharmaceutical production, cultivation of stem cells, and tissue engineering. Pharmaceutical and biotechnology companies carry out mycoplasma testing to investigate altered growth rates, morphological changes, chromosomal aberrations, and metabolism alterations. Mycoplasma testing is used for bulk and final drug products, cell banks, and raw materials. The global mycoplasma testing market is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5% during forecast period. Increasing growth and government support of pharmaceutical and biotechnology industries, strong trend of R&D investments in life science, and rising cell culture contamination will drive the growth of the mycoplasma testing market. In the coming years, emerging markets and increasing pharmaceutical outsourcing are expected to offer growth opportunities for players in the mycoplasma testing market.

By product, kits & reagents segment is expected to grow at the highest growth rate during the forecast period

The kits & reagents segment is projected to register the highest during the forecast period. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques for mycoplasma testing are the important factors driving the growth of this segment.

By technique, PCR segment to record the highest CAGR during the forecast period

PCR segment is projected to register a higher CAGR during the forecast period. Highest CAGR of this segment can be attributed to the high acceptance rate of PCR due to the accuracy, speed, and flexibility provided by this technique in life sciences research. Moreover, this technique offers high sensitivity and a lower turnaround time. PCR is widely used for the detection of mycoplasma in research and biopharmaceutical production. It has been considered an efficient method for the detection of mycoplasma as it is relatively fast, inexpensive, and is not affected by cell culture conditions.

By application type, cell line testing segment to record the highest CAGR during the forecast period

Cell line testing application segment is projected to register a higher CAGR during the forecast period. Factors such as a rapid growth of the biopharmaceutical industry and increasing demand for monoclonal antibodies are driving the growth of this segment.

By end user type, pharmaceutical & biotechnology companies segment to record the highest CAGR during the forecast period

Pharmaceutical & biotechnology companies� end user segment is projected to register a higher CAGR during the forecast period. Pharmaceutical and biotechnology companies primarily carry out large-scale, preparative cell cultures. Significant growth in R&D investments in the pharmaceutical industry is the primary growth driver of this end-user segment. The increase in the number of biotechnology and pharmaceutical patents granted worldwide is also expected to impact the growth of this market.

North America to account for the largest market size during the forecast period.

North America is expected to account for the largest share of this market. The large share of North America is attributed to the high adoption rate of novel technologies and the large number of life science research studies conducted in this region.

Market Dynamics

Driver: Increasing growth and government support for pharmaceutical and biotechnology industries

Pharmaceutical and biotechnology companies are the largest end users in the mycoplasma testing market. Mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for associated markets such as mycoplasma testing.

The pharmaceutical and biotechnology market across several geographies is growing at a significant rate. According to the International Trade Administration, the global pharmaceuticals market is projected to grow from USD 1 trillion in 2015 to USD 1.3 trillion by 2020, at a CAGR of 4.9%. The Indian pharmaceuticals market, as reported by the India Brand Equity Foundation, is expected to reach USD 55 billion by 2020 from USD 36.7 billion in 2016, at a CAGR of 15.92%. The Indian biotechnology sector was valued at an estimated USD 4 billion in 2011; it was projected to reach USD 10 billion by 2015. Strong growth in the pharmaceutical and biopharmaceutical industries will drive the mycoplasma testing market.

Opportunity: Increasing pharmaceutical outsourcing

The R&D expenditure in the pharmaceutical industry is very high. According to PhRMA, its member companies invested an estimated USD 58.8 billion in research and development (R&D) in 2015, an increase of 10.3% from 2014. Contract research organizations act as outsourcing partners for pharmaceutical and biotechnology companies and academic institutes. Many pharmaceutical and biotechnology companies and academic institutes opt to outsource functions like manufacturing, clinical trial management, and drug discovery to CROs. Pharmaceutical research outsourcing enables these organizations to decrease their operational costs. Furthermore, owing to technological advancements and the emergence of new technologies, it is not feasible for companies to undertake all testing functions in-house. CROs can afford to invest in an extensive drug discovery infrastructure as they cater to multiple clients. This makes investing in advanced techniques like PCR, ELISA, and cell line authentication and characterization tests a cost-effective option for CROs. With the help of CROs, pharmaceutical and biotechnology companies can reduce their operational costs and R&D budgets. With the growth in outsourcing R&D activities, the demand for mycoplasma testing services from CROs is estimated to increase. The rise in outsourcing thus provides significant growth opportunities for the market.

Challenge: Dearth of skilled professionals

The success of mycoplasma tests depends mainly on the expertise of the analysts themselves as much as the environmental conditions under which the test is performed. For optimal efficacy, mycoplasma testing needs to be conducted by skilled professionals with sufficient knowledge of the nuances of this field. Handling the instruments used in mycoplasma testing also requires expertise. Consequently, the dearth of a sufficiently skilled workforce poses a key challenge to the growth of the mycoplasma testing market.

Scope of the Report

Report Metric Details Market size available for years 2016�2022 Base year considered 2016 Forecast period 2017�2022 Forecast units Million (USD) Segments covered Product and Services Kits & Reagents PCR Assays Nucleic Acid Detection Kits Elimination Kits & Reagents Stains Standards & Controls Other Kits & Reagents

Services

Instruments By Technique PCR

ELISA

Direct Assays

Indirect Assays

DNA Staining

Microbial Culture Techniques

Enzymatic Methods By Application Cell Line Testing

Virus Testing

End-of Production Cell testing

Other Applications By End User Pharmaceutical & Biotechnology Companies

Contract Research Organizations

Academic Research Institutes

Cell Banks

Other End Users Geographies covered North America, Europe, Asia, RoW Companies covered 11.1 Charles River Laboratories International, Inc

11.2 Merck KGaA

11.3 Lonza Group Ltd.

11.4 ROCHE DIAGNOSTICS (DIVISION OF F. HOFFMAN-LA ROCHE LTD.)

11.5 SGS S.A.

11.6 Thermo Fisher Scientific Inc.

11.7 American Type Culture Collection

11.8 Biounique Testing Laboratories Inc.

11.9 Invivogen

11.10 Promocell GMBH

11.11 Biological Industries Israel Beit Haemek Ltd.

11.12 Wuxi APPTEC

11.13 Norgen Biotek Corporation

The research report categorizes the mycoplasma testing market into the following segments and subsegments:

By Product

Kits & Reagents PCR Assays Nucleic Acid Detection Kits Elimination Kits & Reagents Stains Standards & Controls Other Kits & Reagents

Services

Instruments

By Technique

PCR

ELISA

Direct Assays

Indirect Assays

DNA Staining

Microbial Culture Techniques

Enzymatic Methods

By Application

Cell Line Testing

Virus Testing

End-of Production Cell testing

Other Applications

By End User

Pharmaceutical & Biotechnology Companies

Contract Research Organizations

Academic Research Institutes

Cell Banks

Other End Users

By Region

North America US Canada

Europe Germany UK France Italy Spain Rest of Europe (RoE)

Asia Japan China India Rest of Asia

RoW

Key Market Players

Thermo Fisher Scientific, Inc., Roche Diagnostics, Merck KGaA, Lonza Group Ltd, Charles River Laboratories International, Inc., InvivoGen, PromoCell GmbH, Bionique Testing Laboratories, Inc., and American Type Culture Collection.

Critical questions the report answers:

Where will all these developments take the industry in the long term?

What are the upcoming trends for the mycoplasma testing market?

Which segment provides the most opportunity for growth?

Who are the leading vendors operating in this market?

What are the opportunities for new market entrants?

Frequently Asked Questions (FAQ): Which type of mycoplasma testing product and services are expected to register highest growth rate? Based on product and services, mycoplasma testing market segmented into consumables, instruments and services. The consumables segment is expected to grow at the highest growth rate during the forecast period. The growth of this market is driven mainly by the frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques for mycoplasma testing. Which application is expected to have highest growth rate in the market during forecast period? By application, mycoplasma testing market categorized into cell line testing, virus testing, end-of-production cell testing and other application. The cell line testing segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed rapid growth of the biopharmaceutical industry and increasing demand for monoclonal antibodies. Which is the leading end user segment for mycoplasma testing product and services? Pharmaceutical & biotechnology companies is accounted for the largest share of the mycoplasma testing market in 2017. Who are the key players operating in the mycoplasma testing market? The global mycoplasma testing market is highly competitive and fragmented. The prominent players operating in this market include Charles River Laboratories International, Inc (US), Merck KGaA (Germany), Lonza Group Ltd. (Switzerland), Roche Diagnostics (Switzerland), SGS S.A (Switzerland), Thermo Fisher Scientific Inc. (US), American Type Culture Collection (US), Biounique Testing Laboratories Inc. (US), Invivogen (US), Promocell (Germany), Biological Industries Israel Beit Haemek Ltd. (Israel), WuXi AppTec (China), and Norgen Biotek Corporation (Canada). Which geographical region is dominating in mycoplasma testing market? The global mycoplasma testing market is segmented into North America, Europe, Asia, and the Rest of the World. In 2017, North America dominated the global mycoplasma testing market, followed by Europe. However, the Asia market is estimated to register the highest CAGR during the forecast period.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst